OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis
Yazen Alnefeesi, David Chen‐Li, Ella Krane, et al.
Journal of Psychiatric Research (2022) Vol. 151, pp. 693-709
Closed Access | Times Cited: 106
Yazen Alnefeesi, David Chen‐Li, Ella Krane, et al.
Journal of Psychiatric Research (2022) Vol. 151, pp. 693-709
Closed Access | Times Cited: 106
Showing 1-25 of 106 citing articles:
The antidepressant actions of ketamine and its enantiomers
Jenessa N. Johnston, Ioline D. Henter, Carlos A. Zarate
Pharmacology & Therapeutics (2023) Vol. 246, pp. 108431-108431
Open Access | Times Cited: 72
Jenessa N. Johnston, Ioline D. Henter, Carlos A. Zarate
Pharmacology & Therapeutics (2023) Vol. 246, pp. 108431-108431
Open Access | Times Cited: 72
Ketamine in neuropsychiatric disorders: an update
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 23-40
Closed Access | Times Cited: 48
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 23-40
Closed Access | Times Cited: 48
Canalization and plasticity in psychopathology
Robin Carhart‐Harris, Shamil Chandaria, David Erritzøe, et al.
Neuropharmacology (2022) Vol. 226, pp. 109398-109398
Open Access | Times Cited: 66
Robin Carhart‐Harris, Shamil Chandaria, David Erritzøe, et al.
Neuropharmacology (2022) Vol. 226, pp. 109398-109398
Open Access | Times Cited: 66
Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis
Shakila Meshkat, Yazen Alnefeesi, Muhammad Youshay Jawad, et al.
Psychiatry Research (2022) Vol. 317, pp. 114857-114857
Closed Access | Times Cited: 42
Shakila Meshkat, Yazen Alnefeesi, Muhammad Youshay Jawad, et al.
Psychiatry Research (2022) Vol. 317, pp. 114857-114857
Closed Access | Times Cited: 42
The Role of Ketamine in the Treatment of Bipolar Depression: A Scoping Review
Muhammad Youshay Jawad, Saleha Qasim, Menglu Ni, et al.
Brain Sciences (2023) Vol. 13, Iss. 6, pp. 909-909
Open Access | Times Cited: 36
Muhammad Youshay Jawad, Saleha Qasim, Menglu Ni, et al.
Brain Sciences (2023) Vol. 13, Iss. 6, pp. 909-909
Open Access | Times Cited: 36
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
John H. Krystal, Alfred P. Kaye, Sarah Jefferson, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 49
Open Access | Times Cited: 30
John H. Krystal, Alfred P. Kaye, Sarah Jefferson, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 49
Open Access | Times Cited: 30
Therapeutic mechanisms of psychedelics and entactogens
Boris D. Heifets, David E. Olson
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 104-118
Closed Access | Times Cited: 29
Boris D. Heifets, David E. Olson
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 104-118
Closed Access | Times Cited: 29
A Randomized Double-Blind Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation
Tung‐Ping Su, Cheng‐Ta Li, Wei‐Chen Lin, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 5, pp. 331-339
Open Access | Times Cited: 25
Tung‐Ping Su, Cheng‐Ta Li, Wei‐Chen Lin, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 5, pp. 331-339
Open Access | Times Cited: 25
Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis
Alexandros Matsingos, Marcel Wilhelm, Laila Noor, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 10
Alexandros Matsingos, Marcel Wilhelm, Laila Noor, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 10
The diverse effects of ketamine, jack-of-all-trades: a narrative review
Nicholas David Richards, Simon Howell, Michael Bellamy, et al.
British Journal of Anaesthesia (2025)
Closed Access | Times Cited: 1
Nicholas David Richards, Simon Howell, Michael Bellamy, et al.
British Journal of Anaesthesia (2025)
Closed Access | Times Cited: 1
Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 30
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 30
Role of Psychedelics in Treatment-Resistant Depression
Shubham Kamal, Manish K. Jha, Rajiv Radhakrishnan
Psychiatric Clinics of North America (2023) Vol. 46, Iss. 2, pp. 291-305
Closed Access | Times Cited: 20
Shubham Kamal, Manish K. Jha, Rajiv Radhakrishnan
Psychiatric Clinics of North America (2023) Vol. 46, Iss. 2, pp. 291-305
Closed Access | Times Cited: 20
Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
Johanna Louise Keeler, Janet Treasure, Hubertus Himmerich, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 19
Johanna Louise Keeler, Janet Treasure, Hubertus Himmerich, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 19
Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder
Kevork Danayan, Noah Chisamore, Nelson B. Rodrigues, et al.
Psychiatry Research (2023) Vol. 323, pp. 115133-115133
Closed Access | Times Cited: 17
Kevork Danayan, Noah Chisamore, Nelson B. Rodrigues, et al.
Psychiatry Research (2023) Vol. 323, pp. 115133-115133
Closed Access | Times Cited: 17
Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
Dania Akbar, Taeho Greg Rhee, Felicia Ceban, et al.
CNS Drugs (2023) Vol. 37, Iss. 10, pp. 867-881
Closed Access | Times Cited: 17
Dania Akbar, Taeho Greg Rhee, Felicia Ceban, et al.
CNS Drugs (2023) Vol. 37, Iss. 10, pp. 867-881
Closed Access | Times Cited: 17
Repurposing General Anesthetic Drugs to Treat Depression: A New Frontier for Anesthesiologists in Neuropsychiatric Care
Connor T. A. Brenna, Benjamin I. Goldstein, Carlos A. Zarate, et al.
Anesthesiology (2024) Vol. 141, Iss. 2, pp. 222-237
Open Access | Times Cited: 7
Connor T. A. Brenna, Benjamin I. Goldstein, Carlos A. Zarate, et al.
Anesthesiology (2024) Vol. 141, Iss. 2, pp. 222-237
Open Access | Times Cited: 7
Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada
Carson Chrenek, Bryan Duong, Atul Khullar, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 6
Carson Chrenek, Bryan Duong, Atul Khullar, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 6
At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data
David S. Mathai, Thomas D. Hull, Leonardo Vando, et al.
Journal of Affective Disorders (2024) Vol. 361, pp. 198-208
Open Access | Times Cited: 6
David S. Mathai, Thomas D. Hull, Leonardo Vando, et al.
Journal of Affective Disorders (2024) Vol. 361, pp. 198-208
Open Access | Times Cited: 6
Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression
Farhan Fancy, Nelson B. Rodrigues, Joshua D. Di Vincenzo, et al.
Bipolar Disorders (2022) Vol. 25, Iss. 2, pp. 99-109
Closed Access | Times Cited: 27
Farhan Fancy, Nelson B. Rodrigues, Joshua D. Di Vincenzo, et al.
Bipolar Disorders (2022) Vol. 25, Iss. 2, pp. 99-109
Closed Access | Times Cited: 27
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
Muhammad Youshay Jawad, Joshua D. Di Vincenzo, Sebastian Badulescu, et al.
Neuropharmacology (2022) Vol. 223, pp. 109299-109299
Closed Access | Times Cited: 22
Muhammad Youshay Jawad, Joshua D. Di Vincenzo, Sebastian Badulescu, et al.
Neuropharmacology (2022) Vol. 223, pp. 109299-109299
Closed Access | Times Cited: 22
Clinical pharmacological innovation in the treatment of depression
Jeffrey M. Witkin, Lalit K. Golani, Jodi L. Smith
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 349-362
Closed Access | Times Cited: 13
Jeffrey M. Witkin, Lalit K. Golani, Jodi L. Smith
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 4, pp. 349-362
Closed Access | Times Cited: 13
The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis
Tuuli M. Hietamies, L. Alison McInnes, Andrew Klise, et al.
Journal of Affective Disorders (2023) Vol. 335, pp. 484-492
Open Access | Times Cited: 13
Tuuli M. Hietamies, L. Alison McInnes, Andrew Klise, et al.
Journal of Affective Disorders (2023) Vol. 335, pp. 484-492
Open Access | Times Cited: 13
Experiences of Awe Mediate Ketamine’s Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression
Julia Aepfelbacher, Benjamin Panny, Rebecca B. Price
Biological Psychiatry Global Open Science (2024) Vol. 4, Iss. 4, pp. 100316-100316
Open Access | Times Cited: 5
Julia Aepfelbacher, Benjamin Panny, Rebecca B. Price
Biological Psychiatry Global Open Science (2024) Vol. 4, Iss. 4, pp. 100316-100316
Open Access | Times Cited: 5
Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review
Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 5
Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 5
